The BioPharm Brief: Oncology, Growth, Validation

May 22, 08:26 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief covers major developments in oncology, rare disease therapeutics, and ADC manufacturing, including positive Phase 3 data for Kelun-Biotech’s sac-TMT in triple-negative breast cancer, promising hypochondroplasia results for vosoritide, and new perspectives on risk-based cleaning validation for highly potent drug manufacturing.

Share
Subscribe
Next
The BioPharm Brief: Gene Editing, Myeloma, Neuroregeneration
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief